Comparison between processes of HTA, pharmaceutical pricing and reimbursement, and their transparency in Germany and Poland

Hanna Wüller,

Christoph Sowada,

Tomasz Bochenek


This paper focuses on HTA, pricing and reimbursement of pharmaceuticals in Germany and Poland. The authors analyzed processes of decision making related to pharmaceutical reimbursement, as well as their transparency. Both Germany and Poland have developed complex processes of pharmaceutical pricing and reimbursement, as well as incorporated HTA into decision making procedures.In Germany the stakeholders involvement and transparency of processes seem to be to higher than in Poland.

Słowa kluczowe: ceny i refundacja leków, Niemcy, ocena technologii medycznych, polityka lekowa, Polska, przejrzystość

Busse R., Blümel M., Germany: health system review, “Health Systems in Transition” 2014; 16(2): 1–296.

Sagan A., Panteli D., Borkowski W. et al., Poland: Health system review, “Health Systems in Transition” 2011; 13(8): 1–193.

Sorenson C., Chalkidou K., Reflections on the evolution of health technology assessment in Europe, “Health Economics, Policy and Law” 2012; 7(01): 25–45.

Kerr A., Todd C., Hebborn A., Ulyate K., comparison of international health technology assessment systems does the perfect system exist?, “Value in Health” 2014; 17(7): A441.

The European Parliament and the Council, DIRECTIVE 2004/109/EC of 15 December 2004 on the harmonisation of transparency requirements in relation to information about issuers whose securities are admitted to trading on regulated market and amending Directive 2001/34/EC,; accessed: 10.04.2015.

Henschke C., Sundmacher L., Busse R., Structural changes in the German pharmaceutical market: Price setting mechanisms based on the early benefit evaluation, “Health Policy, Health Policy” 2013; 109(3): 263–269.

Kreis J., Schmidt H., Public engagement in health technology assessment and coverage decisions: study of experiences in France, Germany, and the United Kingdom, “Journal of Health Politics, Policy and Law” 2013; 38(1): 89–122.

Gulácsi L., Rotar A. M., Niewada M., Löblová O., Rencz F., Petrova G., Boncz I., Klazinga N.S., Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria, “The European Journal of Health Economics” 2014; Suppl 1: 13–25.

Gerber-Grote A., Sandmann F. G., Zhou M., Ten Thoren C., Schwalm A., Weigel C., Balg C., Mensch A., Mostardt S., Seidl A., Lhachimi S.K., Decision making in Germany: Is health economic evaluation as supporting tool sleeping beauty? “Zeitschrift Für Evidenz, Fortbildung Und Qualität Im Gesundheitswesen“ 2014; 108(7): 390–396.

Greiner W., von der Schulenburg J.M.G., HTA in Germany: very special and specific. “The European Journal of Health Economics“ 2010; 11(1): 1–3.

Gerber A., Stock S., Dintsios C.-M., Reflections on the changing face of German pharmaceutical policy: how far is Germany from value-based pricing? “PharmacoEconomics” 2011; 29(7): 549–553.

Jakubiak-Lasocka, J., Jakubczyk M., Cost-effectiveness versus cost-utility analyses: What are the motives behind using each and how do their results differ? Polish example, “Value in Health Regional Issues” 2014; 4: 66–74.

Niewada M., Polkowska M.A., Jakubczyk M., Golicki D., HT4 what determines the recommendations issued by Polish health technology agency (AHTAPol)?, “Value in Health” 2011; 14(7): A241.

Balvanyos J., Alnwick K., Proudfoot C., Economic evidence requirements: comparison between HTA agencies and implications for manufacturers, “Value in Health” 2010; 11: A424.

Bechtel B., Welte R., PHP78 convergent tendencies in budget impact analysis across Europe and beyond: Germany – Donʼt lose out on the “Zeitgeist”!, ”Value in Health” 2011; 14(7): A347.

Kujawska A. Nogas G., Transparency of drug reimbursement in Poland, “Value in Health” 2010; 13(7): A278.

Jebrail F., Duong M., Shum D., Analysis of transparency amongst international health technology assessment organizations, “Value in Health” 2013; 16(7): A481–A482.

Marusakova E., Bielik J., Application of health technology assessment and pharmacoeconomics in the decision-making process in selected EU member states, “Value in Health” 2013; 16(7): A679.

Obradovic M., Rauland M., Inclusion and consideration of patient p in among early benefit assessments, “Value in Health” 2014; (17): A440.

Sandmann F.G., Gerber A., Lhachimi S.K., PHP124 – IQWIG’s efficiency frontier approach: Fit for purpose!, “Value in Health“ 2013; 16(7): A473.

WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Glossary,; accessed: 10.04.2015.

Bundesministerium für Gesundheit, Die Spreu vom Weizen trennen: Das Arzneimittelmarktneuordnungsgesetz (AMNOG),; accessed: 12.04.2015.

IQWiG, Contracting agencies and funding of iqwig,; accessed: 10.04.2015.

Bochenek T., Risk-sharing, individual price agreements and reference pricing – recent developments in Polish pharmaceutical policy, “FARMAKOÖKONȮMIA. IME – The Journal of Healthcare Managers” 2012; 10: 71–73.

Bundesministerium für Gesundheit, Arzneimittel: Die wichtigsten Regelungen für Zuzahlung und Erstattung im Überblick 2014,; accessed: 10.04.2015.

Agency for Health Technology Assessment, Guidelines for conducting Health Technology Assessment (HTA),; accessed: 10.04.2015

Institute for Quality and Efficiency in Health Care, methods,; accessed: 10.04.2015.

International Monetary Fund, Code of Good Practices on Transparency in Monetary and Financial Policies, 2000,; accessed: 10.04.2015.

European Commission, Transparency Directive 89/105/EEC, 2015,; accessed: 10.04.2015.